Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type

Paloma Silva de Souza, André L.S. Cruz, João P.B. Viola and Raquel C. Maia

Key words
Inhibitors of apoptosis proteins, microparticles, multidrug resistance, NFκB, P-glycoprotein

Correspondence
Raquel C. Maia, Laboratório de Hemato-Oncologia Celular e Molecular, Instituto Nacional de Cancer, Praça da Cruz Vermelha 23/6º andar, Rio de Janeiro 20230-130, Brazil.
Tel: +55-21-3207-1198; Fax: +55-21-3207-1808; E-mail: rcmia@inca.gov.br

Funding Information
This study was supported by Instituto Nacional de Ciência e Tecnologia (INCT), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Programa de Oncobiologia and Fundação de Amparo à Pesquisa do Rio de Janeiro (FAPERJ).

Multidrug resistance (MDR) is considered a multifactorial event that favors cancer cells becoming resistant to several chemotherapeutic agents. Numerous mechanisms contribute to MDR, such as P-glycoprotein (Pgp/ABCB1) activity that promotes drug efflux, overexpression of inhibitors of apoptosis proteins (IAP) that contribute to evasion of apoptosis, and oncogenic pathway activation that favors cancer cell survival. MDR molecules have been identified in membrane microparticles (MP) and can be transferred to sensitive cancer cells. By co-culturing MP derived from MDR-positive cells with recipient cells, we showed that sensitive cells accumulated Pgp, IAP proteins and mRNA. In addition, MP promoted microRNA transfer and NFκB and Yb-1 activation. Therefore, our results indicate that MP can induce a multifactorial phenotype in sensitive cancer cells.

Material and Methods

Cell lines and cell culture. In this study, we used the human breast adenocarcinoma MCF7, human lung carcinoma A549, and...
human CML K562 cell lines, which were purchased from ATCC, and the K562 MDR variant Lucena cell line, as described previously. Cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated FBS and 2 mM L-glutamine, and maintained at 37°C under a 5% CO₂ humidified atmosphere. Lucena cells were cultured as previously described.

For co-cultures, sensitive cells were plated on the bottom of 6-well or 24-well plastic culture plates (3 × 10⁵ and 5 × 10⁴ cells, respectively). Cells were cultured for 24 h to ensure sensitive cell adherence, and Lucena resistant cell line (2 × 10⁵ cells/mL) was co-incubated in the same culture medium separated by permeable PET transwell inserts with 3.0-μm pores (Millicell from Millipore - Darmstadt, Germany). Sensitive cells were also co-cultured with isolated MP (described below) from Lucena cells for 24 h.

For conditioned media assays, Lucena cells were cultured without drugs and centrifuged at 1000 g for 10 min. Afterwards, conditioned medium was filtered through a 0.22-μm filter (TPP) and added to sensitive cell lines for 24 h.

Membrane microparticles purification. Lucena cells were cultured (2.5 × 10⁴) and used for MP purification by differential centrifugation. First, cells were removed by centrifugation at 1000 g for 10 min. To pellet whole cells, the supernatant was centrifuged at 5000 g for 5 min. Next, the supernatant was ultra-centrifuged (Sorvall RC6°, Thermo) at 30 000 g for 20 min at 4°C to pellet the MP. MP were then washed in sterile PBS, and centrifuged as before.

Isolated MP were identified using flow cytometry (FacsScalibur and Accuri, BD) after 15 min of FITC-annexin V staining at room temperature and were also analyzed for protein and RNA content.

Fluorescent microspheres of 0.5 and 1.0 μm (Spherotech, Carlsbad, CA, USA) were used to identify size of MP.

Western blotting and subcellular fractionation. Total cell lysates and western blotting were performed for survivin (R&D Systems, Minneapolis, MN, USA), XIAP (R&D Systems), c-IAP1 (R&D Systems), IκBα (Cell Signaling), Phospho-Akt Ser473 (Cell Signaling) and Yb-1 (Abcam, San Francisco, CA, USA) as previously described.

The subcellular fractionation analysis of NF-κB (Cell Signaling) and the subcellular fraction to lamina B (Calbiochem - Brazil) was performed according to the manufacturer's instructions (NE-PER Nuclear and Cytoplasmatic Extraction Reagent Kit; Thermo Scientific, Waltham, MA, USA). To assess Pgp expression (monoclonal anti-Pgp clone C219, 1:10,000), cell lysates were prepared as previously described.

Total protein was loaded onto 3–8% gradient NuPAGE Novex Tris-acetate gels (Invitrogen), and proteins were transferred to Hybond-P membranes (GE Healthcare, Buckinghamshire, UK). We normalized the total protein to β-actin (Sigma-Aldrich Corp., St. Louis, MO, USA) and Na⁺/K⁺ATPase (Cell Signaling) and the subcellular fraction to lamin B (Calbiochem - Darmstadt, Germany) and HSC70 (Santa Cruz, Dallas, TX, USA).

To visualize protein expression, we used the ECL detection system according to the manufacturer’s instructions (GE Healthcare).

Flow cytometry analysis of P-glycoprotein expression. For Pgp immunodetection, MP derived from Lucena cells, MP derived from parental K562 cells, and recipient cell lines after 24 h of co-culturing (MCF7 and A549) were blocked with 1% BSA for 15 min. Pgp cell surface expression was measured after incubation with an anti-Pgp PE-conjugated monoclonal antibody (clone UIC2; Coulter, Brea, CA, USA) for 30 min through flow cytometry according to the manufacturer’s instructions.

Determination of P-glycoprotein activity by flow cytometry. To analyze Pgp activity, MCF7 and A549 cells were co-incubated with 200 ng/mL rhodamine-123 (Rho-123) and 200 ng/mL cyclosporine A (CsA) for 45 min at 37°C in a 5% CO₂ humidified atmosphere. Cells were washed in ice-cold PBS and re-incubated with CsA for an additional 45 min under the same conditions. Cells were analyzed by flow cytometry, and the results were expressed as the mean fluorescence intensity ratio (MFI) of cells incubated with Rho-123 and CsA, which was divided by the MFI of cells with Rho-123 alone after subtracting the MFI accounting for auto-fluorescence.

Immunofluorescence. Cells were plated on coverslips, and after 24 h of co-culturing, cells were fixed with 4% paraformaldehyde for 20 min and incubated with 10 μM NH₄Cl for 10 min. The subsequent procedures were performed as previously described. We used anti-Pgp (clone UIC2; Coulter), anti-Yb-1 (Abcam) and anti-NF-κB primary antibodies and Alexa 488-conjugated goat anti-rabbit IgG or Alexa 594-conjugated goat anti-mouse IgG secondary antibodies (Molecular Probes, Eugene, OR, USA). Images were acquired with the NIS-Elements F2.30 software, using an Eclipse E200 Nikon microscope connected to a Digital Sight system.

Apoptosis detection. After 24 h of co-culturing, cells were treated with cisplatin (Accord Farmaceutica LTDA, São Paulo, Brazil), etoposide (Darrow, Rio de Janeiro, Brazil) and paclitaxel (Evolabis, São Paulo, Brazil) for 24 h, in the presence or absence of co-cultured cells. The percentage of apoptotic cells was assessed using the Annexin V/PI assay (Genzyme Diagnostics, Cambridge, MA, USA), according to the manufacturer’s instructions.

Real-time quantitative PCR analysis. qRT-PCR was performed to determine ABCB1, Yb-1, BIRC5 (survivin), BIRC2 (c-IAP1) and BIRC4 (XIAP) mRNA expression levels. Total cellular RNA was isolated using Trizol (Invitrogen) and mRNA from isolated MP was isolated using the mirVana miRNA Isolation Kit according to the manufacturer’s instructions (Life Technologies, Carlsbad, CA, USA). RNA was treated with DNase (Ambion, Carlsbad, CA, USA) to eliminate contaminating DNA, and cDNA was synthesized with the Ready-To-Go T-Primed first-strand kit (GE Healthcare). Gene amplification and analysis were performed as previously described. β-actin was used to normalize C values, and all probes were purchase from Applied Biosystems (Carlsbad, CA, USA).

qRT-PCR for miRNA. miRNA from isolated MP and cell lines were extracted using the mirVana miRNA Isolation kit (Ambion, Life Technologies), according to the manufacturer’s instructions. Then, miRNA concentrations were quantified using a NanoDrop 1000 (Thermo Scientific), and cDNA was synthesized using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). qRT-PCR was performed using a primer-specific TaqMan Kit (Applied Biosystems) for hsa-miR-27a, hsa-miR-21 and hsa-miR-451. The miRNA expression levels were normalized to the expression levels of the mature miRNA control RN6B. These qRT-PCR experiments were carried out using the StepOne Real-Time PCR system.

Statistical analysis. Student’s t-test or one-way ANOVA were applied for all data analysis. Results were considered statistically significant at P < 0.05.

Results
Identification of multidrug resistance chronic myeloid leukemia cell-derived membrane microparticles. Recently, MP from MDR cell lines have been reported to...
mediate the transfer of Pgp to drug sensitive ALL cells.\(^{(12)}\)

Based on this information, MP derived from CML sensitive cells and a drug-resistant variant were purified and analyzed as described in the Material and Methods. Our results demonstrated that both sensitive and drug-resistant CML cells were able to spontaneously release MP into \textit{in vitro} culture conditions, representing 52.22\% and 50\%, respectively, of the FITC-annexin V positive population after phosphatidylserine exposure (Fig. 1).

We confirmed that MDR cell-derived MP could transport Pgp onto the cell surface. Approximately 22\% of the MP-gated population was positive for Pgp. However, MP derived from sensitive cells did not contain Pgp (Suppl. Fig. S1).

\textbf{Characterization of multidrug resistance chronic myeloid leukemia cell-derived membrane microparticles.} In MDR cell-derived MP, we analyzed soluble proteins (c-IAP-1, XIAP and survivin) and RNA (mRNA and miRNA) that are involved in the multifactorial resistant phenotype. First, our data revealed that CML MDR-positive cell-derived MP contained anti-apoptotic proteins, such as survivin, c-IAP-1 and a small amount of XIAP (Fig. 2a). Their respective mRNA, \textit{BIRC5} and \textit{BIRC2}, but not \textit{BIRC4}, were contained in MP in addition to \textit{ABCB1} mRNA (Fig. 2b).

We also analyzed whether MP could transport miRNA, which are non-coding, small RNA molecules that can induce mRNA degradation or transcriptional repression by binding to complementary 3'UTR sites in the target mRNA and, consequently, regulating gene expression.\(^{(20)}\) miR-27a, miR-451 and miR-21 have been shown to be related to Pgp expression and can also contribute to chemoresistance in tumor cells.\(^{(21,22)}\) Here, we found that drug-resistant CML cell-derived MP were able to transport miR-451, miR-21 and small amounts of miR-27a (Fig. 2c).

\textbf{Sensitive cells acquired a resistant phenotype through intercellular transfer of multidrug resistance proteins and RNA.} To determine the effect of drug-resistant CML cell-derived MP during resistant phenotype acquisition in non-MDR cell lines, we co-cultured recipient cells (A549 and MCF7) with MDR-positive donor cells (Lucena) for 24 h. Co-culture conditions used Transwell inserts to avoid intracellular contamination and cell–cell contact (see Material and Methods). Initially, our results showed that A549 and MCF7 cells acquired Pgp protein and mRNA expression (Fig. 3a,b).

Afterwards, we investigated survivin, c-IAP1 and XIAP expression in recipient cells following co-culturing with MDR-positive donor cells. A549 recipient cells clearly showed an increase in all three IAP proteins and mRNA expression after co-culturing. However, MCF7 recipient cells showed only a minor enhancement of XIAP protein expression and no increase of \textit{BIRC2} mRNA expression after co-culturing (Fig. 3c,d). Changes in the mRNA expression profile of A549 and MCF7 cells were confirmed by culturing these cells with isolated MP derived from Pgp-positive cells (Suppl. Fig. S2).

Moreover, A549 and MCF7 cells cultured with conditioned media from MDR-positive cells showed no change in Pgp and IAP protein expression levels (Suppl. Fig. S3). These results indicate that MP transfer proteins and mRNA in a cell-line-dependent manner.

To evaluate whether acquiring Pgp expression and enhancement of survivin, XIAP and c-IAP1 expression could, in fact, induce the MDR phenotype in recipient cells, we tested Pgp efflux pump activity and apoptosis inhibition using chemotherapeutic agents. As shown in Figure 4, A549 and MCF7 recipient cells acquired functional Pgp with little efflux pump activity after co-culturing with an MDR-positive donor cell line (MFI = 1.3 and 1.4, respectively). To analyze apoptosis, A549 and MCF7 cell lines were treated with cisplatin and paclitaxel, respectively, for 24 h after co-culturing with a Pgp-positive donor cell line. The apoptosis index of A549 cells was reduced from 40% to approximately 6\% after co-culture with MP (Fig. 4b). MCF7 cells showed a similar reduction, from 30\% to approximately 14\% (Fig. 4c). These results show that MDR cell-derived MP can induce a drug resistant phenotype in sensitive cell lines.

\textbf{Oncogenic-related pathways contribute to the multifactorial resistance phenotype following the transfer of multidrug resistance proteins and RNA to sensitive cells.} Constitutive activation of the NFκB pathway has been observed in several solid and hematological neoplasms and has been associated with oncogenesis by controlling several key mechanisms, including anti-apoptotic and resistance gene regulation.\(^{(23)}\) Our results demonstrated that \textit{BIRC4} mRNA was not contained in MP derived from resistant cells (Fig. 2b). However, we observed \textit{BIRC4} mRNA upregulation in both recipient cells after co-culturing with MDR-positive donor cells (Fig. 3c and Suppl. Fig. S2, respectively). Thus, we evaluated NFκB pathway activation through IkBα regulation and NFκB subcellular localization. IkBα levels were reduced in A549 and MCF7 cells after co-culturing with MDR cell-derived MP (Fig. 5a). Moreover, we observed a subcellu-

\begin{center}
\textbf{Fig. 1.} Cancer cells spontaneously secrete microparticles in \textit{in vitro} culture. Isolated membrane microparticles (MP) were identified by flow cytometry in a dot plot of forward light scattering (FSC) versus side light scattering (SSC). Size of MP was characterized using Fluorescent Microspheres of 0.5 and 1.0 μM. The majority population of cancer cells derived-MP is represented in black and it ranges between 0.5 μM (purple) and 1.0 μM (red) (a). 52.22\% of the gated events of KS62 cells derived-MP (b) and 50\% of Lucena cells derived-MP were FITC-annexin V-positive (c).
\end{center}
lar redistribution of NFκB with predominant nuclear localization after co-culturing (Fig. 5b,c). These results strongly suggest the functional NFκB pathway involvement in intrinsic BIRC4 gene regulation. Likewise, nuclear NFκB may have contributed to intrinsic ABCB1 and IAP expression in recipient cells (Fig. 3).
We further investigated Yb-1 expression and its subcellular localization in recipient cells. Yb-1 is a multifunctional protein also involved in transcriptional regulation and drug resistance. Yb-1 has been reported to bind to the ABCB1 promoter region and positively regulate its transcription.\(^{15,24}\) Although no changes were observed in Yb-1 protein expression (Fig. 5a) and mRNA expression levels (data not shown) after co-culturing with MP, Yb-1 was differentially distributed in recipient cells. We observed a perinuclear subcellular localization of Yb-1 in A549 cells with no change in nuclear and cytoplasmatic localization after co-culturing. However, in MCF7 cells, we detected nuclear foci of Yb-1 after co-culturing (Fig. 5b,d). The nuclear organization in foci of Yb-1 in MCF7 cells suggests Yb-1 participation in ABCB1 mRNA transcription.

Multidrug resistance cell-derived membrane microparticles transfer oncogenic and resistance miRNA to sensitive cells. Our results showed that MDR cell-derived MP contained miR-27a, miR-451 and miR-21 from donor cells (Fig. 2c). Indeed, we evaluated the transfer of miR-27a, miR-451 and miR-21 from MDR cell-derived MP to recipient cells. Our results showed
that miR-27a and miR-451 were upregulated in A549 and MCF7 recipient cells after co-culturing. In addition, MCF7 cells showed an increase in oncogenic miR-21 expression levels after co-culturing (Fig. 6a,b). These data suggest that miR-27a and miR-451 may contribute to the positive regulation of intrinsic ABCB1 mRNA expression in recipient cells and that miR-21 may contribute to malignant tumor potential. In addition, we analyzed the Akt activation in both recipient cells, due to the fact that this kinase can be related to NFκB activation via miR-21. After co-culturing, MCF7 showed an increase in phosphorylated Akt protein (Fig. 6c).

Discussion

In this study, we showed that drug-resistant CML cell-derived MP could transfer anti-apoptotic molecules besides Pgp to sensitive breast and lung tumor cells. In addition, we demonstrated that these MP induced changes in the oncogenic phenotype of drug-sensitive recipient cancer cells.

The selectivity of Pgp-positive MP binding was recently discussed by Jaiswal et al., who report that MP secreted from MDR breast cancer cells only transferred Pgp to malignant breast cells. In addition, they showed that MP derived from resistant ALL cells could transfer Pgp to non-leukemic cells. However, Pasquier et al. show that MP derived from epithelium and mesenchymal cancer cells interacted with endothelial cells. Here, our results show that MP secreted from drug-resistant CML cells could transfer Pgp/ABCB1 to sensitive breast and lung tumor cells, thus displaying no cell-type selectivity. Moreover, in A549 cancer cells, we observed an increase in survivin, cIAP1 and XIAP protein expression, which suggests that CML cell-derived MP could transfer IAP molecules to lung cancer cells but were unable to transfer these proteins to breast cancer cells. Survivin protein has been previously detected in exosomes (vesicles smaller than MP that are derived from intracellular organelles) secreted from a cervical cancer cell line and from prostate cancer patients. Another study using cervical cancer cells showed that cIAP1 and XIAP proteins were enriched in MP after immunoblotting overexposure but not in pure MP fractions. Nevertheless, in this study, we described for the first time the presence of IAP mRNA in CML cell-derived MP.

The transfer of Pgp via MP derived from MDR cancer cells has been reported as a potent mediator of resistance, due to its
functional drug efflux pump activity. Here, we confirmed that sensitive A549 cells acquired cisplatin and etoposide (data not shown) drug resistance following co-culturing. However, cisplatin is not a chemotherapeutic drug substrate for Pgp, and, thus, evasion of the cisplatin-induced apoptosis displayed by A549 cells must have been acquired through another mechanism. Gong et al. propose that drugs can be sequestered by MP, specifically daunorubicin and doxorubicin, and this sequestration might contribute to resistance acquisition. However, considering MP content and transfer ability, we suggest that concomitant expression of IAP and Pgp induces a multifactorial resistant phenotype in A549 cells. These data are supported by our previous study, which showed that XIAP contributed to cisplatin and vincristine drug resistance in CML cells with inhibited Pgp activity. However, MCF7 cells showed paclitaxel-induced apoptotic evasion after co-culturing. Because no IAP protein expression changes were observed in MCF7 cells, other than a slight increase in XIAP levels, we assume that paclitaxel resistance in MCF7 cells results from Pgp expression and activity.

Furthermore, we showed that MDR-positive MP induced changes in the NFκB/p65 expression profile in both sensitive recipient cell lines. NFκB is an oncogenic transcription factor that forms homo/heterodimers, and after stimulation, its nuclear localization can regulate cell differentiation, proliferation and survival. In the canonical pathway, NFκB translocation from the cytoplasm to the nucleus occurs following IκBα phosphorylation and degradation. Here, we demonstrated that IκBα degradation and nuclear NFκB localization occurred in A549 and MCF7 cells after co-culturing. Our data suggest that miR-21 contained in MDR-positive MP may regulate the NFκB pathway in recipient cells via Akt phosphorylation. Iliopoulos et al. demonstrated that miR-21 induced cellular transformation and PTEN tumor suppressor gene inhibition, which consequently promoted Akt and NFκB activation. In addition, Pasquier et al. showed that cancer cell-derived MP induced Akt phosphorylation in endothelial recipient cells.

Therefore, we suggest that the NFκB pathway is activated in MCF7 cells via miR-21 transfer by MDR-positive MP. However, no changes in miR-21 expression levels were observed in A549 cells after co-culturing, which indicates that another pathway was activated. However, a variety of miR that have
been associated with NFkB activation can be transferred by MP. Indeed, an MP microRNA array would be useful to investigate specific NFkB pathway activation. Nevertheless, we suggest that nuclear NFkB is associated with endogenous IAP and Pgp mRNA expression, mainly BIRC4, which was not transported by MP but was upregulated in recipient cells.

We identified changes in the Yb-1 localization profile in recipient cells after co-culturing. Overexpression of the Yb-1 transcription factor has been described in solid and hematological cancers, and its nuclear localization has been associated with a poor prognosis. (37) Here, we observed no changes in Yb-1 expression levels; however, Yb-1 was observed as nuclear foci in MCF7 cells, indicating its transcriptional activity. Yb-1 expression levels; however, Yb-1 was observed as nuclear foci in MCF7 cells, indicating its transcriptional activity. Yb-1 was observed as nuclear foci in MCF7 cells, indicating its transcriptional activity.

After co-culturing with MDR-positive MP, we observed perinuclear Yb-1 staining, which suggests binding to RNA in the endoplasmic reticulum. This phenomenon is associated with NF-kappaB (NF-κB), which contributes to MDR. In summary, resistant cancer cell-derived MP carry and transfer MDR and anti-apoptotic molecules to sensitive cancer cells, which can then establish drug resistance. In addition, MP induce the activation of oncogenic pathways and transfer miR, which contribute to the malignant and multifactorial resistant phenotypes of these cells (Fig. 7).

**Disclosure Statement**

The authors have no conflict of interest to declare.

**References**

1. Gosttessman MM. Mechanisms of cancer drug resistance. *Anna Rev Med* 2002; 53: 615–27.
2. Gillies JF, Efferth T, Remacle T. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. *Biochim Biophys Acta* 2007; 1775: 237–62.
3. Gosttessman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer* 2002; 2: 48–58.
4. Vasconcelos FC, Silva KL, Souza PS et al. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. *Cytometry B Clin Cytom* 2011; 80: 158–66.
5. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gosttessman MM. Drug resistance: still a daunting challenge to the successful treatment of AML. *Drugs Resist Updat* 2012; 1–2: 62–9.
6. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. *Nat Rev Drug Discov* 2012; 11: 109–24.
7. Nestal de Moraes G, Souza PS, Costas FC, Vasconcelos FC, Reis FR, Maia RC. The interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia. *Leuk Res Treat* 2012; 2012: 671–2.
8. Souza PS, Vasconcelos FC, De Souza Reis FR, Nestal de Moraes G, Maia RC. P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. *Int J Oncol* 2011; 39: 325–33.
9. Reis FR, Vasconcelos FC, Pereira DL, Moellmann-Coelho A, Silva KL, Maia RC. Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia. *Oncol Rep* 2011; 27: 471–8.
10. Silva KL, de Souza PS, Nestal de Moraes G, Moellmann-Coelho A, Vasconcelos FC, Maia RC. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells. *Leuk Res* 2013; 37: 1350–8.
11. Ambudkar SV, Sauna ZE, Gosttessman MM, Szakacs G. A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein into carcinoma cells. *J Intrafollicul Oncol* 2011; 39: 325–33.
12. Bemwhy M, Combes V, Lee E, Gong J, Bouhore A, Grau GE. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. *Leukemia* 2009; 23: 1643–9.
13. EL Andaloossi S, Mager I, Breakfield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. *Nat Rev Drug Discov* 2012; 13: 347–57.
14. Jaiswal R, Gong J, Sambasivam S et al. Microparticle-associated nucleic acids mediate trait dominance in cancer. *FASEB J* 2012; 26: 420–9.
15. Kwano M, Uchimura T, Hayakawa H et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. *Cancer Sci* 2003; 94: 9–14.
16. Kim HJ, Hawke N, Baldwin AS, NF-kB and IKK as therapeutic targets in cancer. *Cell Death Differ* 2006; 13: 738–47.
17. Ramujkneek VM, Trandade GS, Wagnér-Souza K et al. Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1. *An Acid Bras Cierne* 2001; 73: 57–69.
18. Pasquier J, Galas L, Boulangé-Lecomte C et al. Different modalities of intercellular membrane exchanges mediate cell-to-cell P-glycoprotein transfer in MCF-7 breast cancer cells. *J Biol Chem* 2012; 28: 7734–87.
19. Brimacombe KR, Hall MD, Auld DS et al. A dual-fluorescence high-throughput cell line system for probing multidrug resistance. *Assay Drug Dev Technol* 2009; 7: 233–49.
20. Medina PP, Slack FJ. microRNAs and cancer: an overview. *Cell Cycle* 2008; 7: 2485–92.
21. Zhu H, Wu H, Liu X et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. *Biochem Pharmacol* 2008; 76: 582–8.
22. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad G. Hyaluronan-CD44 interaction with protein kinase C epsilon promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapist resistance in breast tumor cells. *J Biol Chem* 2009; 284: 26533–46.
contents and the amounts of extracellular microvesicles released from HPV-positive cancer cells. *Int J Cancer* 2013; **133**: 1631–42.
31 Gibalová L, Sedlák J, Labudová M *et al.* Multidrug resistant Pgp-positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein-mediated drug efflux activity. *Gen Physiol Biophys* 2009; **28**: 391–403.
32 Gong J, Luk F, Jaiswal R, George AM, Grau GE, Bebawy M. Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance. *Eur J Pharmacol* 2013; **721**: 116–25.
33 de Souza PS, da Cunha Vasconcelos F, Silva LF, Maia RC. Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells. *Tumour Biol* 2012; **33**: 943–56.
34 Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. *Nat Immunol* 2011; **12**: 695–708.
35 Iliopoulos D, Jaeger SA, Hirsch A, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. *Mol Cell* 2010; **39**: 493–506.
36 Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-κB signaling. *J Mol Cell Biol* 2011; **3**: 159–66.
37 Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 YB-1 and its functions. *Biochemistry (Moscow)* 2011; **76**: 1402–33.
38 Chatterjee M, Ranco C, Stühmer T *et al.* The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. *Blood* 2008; **111**: 3714–22.
39 Hayakawa H, Uchiumi T, Fukuda T *et al.* Binding capacity of human YB-1 protein for RNA containing 8-oxoguanine. *Biochemistry* 2002; **41**: 12739–44.
40 Li H, Yang BB. Friend or foe: the role of microRNA in chemotherapy resistance. *Acta Pharmacol Sin* 2013; **34**: 870–9.
41 Feng DD, Zhang H, Zhang P *et al.* Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. *J Cell Mol Med* 2011; **15**: 2164–75.

Supporting Information

Additional supporting information may be found in the online version of this article:

**Fig. S1.** Microparticles derived from multidrug resistant (MDR) cells transport Pgp proteins.

**Fig. S2.** Isolated multidrug resistant (MDR)-positive MP transfer ABCB1, BIRC5, BIRC4 and BIRC2 to Pgp-negative recipient cells.

**Fig. S3.** Conditioned medium (CM) from multidrug resistant (MDR)-positive cells confers no effect on P-glycoprotein and inhibitors of apoptosis proteins (IAP) proteins expression.